These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 21877601)
41. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety. Kyllönen LE; Eklund BH; Pesonen EJ; Salmela KT Transplantation; 2007 Jul; 84(1):75-82. PubMed ID: 17627241 [TBL] [Abstract][Full Text] [Related]
42. Calcineurin inhibitor-free immunosuppressive strategy in elderly recipients of renal allografts from deceased donors: 1-year results from a prospective single center trial. Arbogast HP; Hoffmann JN; Illner WD; Hillebrand GF; Fischereder M; Jauch KW; Land W Transplant Proc; 2009; 41(6):2529-32. PubMed ID: 19715968 [TBL] [Abstract][Full Text] [Related]
43. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study. Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788 [TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids. Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406 [TBL] [Abstract][Full Text] [Related]
45. Effect of basiliximab on renal allograft rejection within 1 year after transplantation. Lee BM; Oh CK; Jin SH; Kim JH; Kim SJ; Kim H; Shin GT Transplant Proc; 2006 Sep; 38(7):2025-8. PubMed ID: 16979988 [TBL] [Abstract][Full Text] [Related]
46. In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development. Todeschini M; Cortinovis M; Perico N; Poli F; Innocente A; Cavinato RA; Gotti E; Ruggenenti P; Gaspari F; Noris M; Remuzzi G; Casiraghi F J Immunol; 2013 Sep; 191(5):2818-28. PubMed ID: 23913968 [TBL] [Abstract][Full Text] [Related]
47. Evaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients. Pennington CA; Tischer SM; Lee E; Lee S; Sindelar J; Park JM Pharmacotherapy; 2015 Aug; 35(8):748-54. PubMed ID: 26234282 [TBL] [Abstract][Full Text] [Related]
49. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal. Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440 [TBL] [Abstract][Full Text] [Related]
50. Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized study. Sheashaa HA; Bakr MA; Ismail AM; Gheith OE; El-dahshan KF; Sobh MA; Ghoneim MA Am J Nephrol; 2005; 25(3):221-5. PubMed ID: 15908741 [TBL] [Abstract][Full Text] [Related]
51. Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis. Liu Y; Zhou P; Han M; Xue CB; Hu XP; Li C Transplant Proc; 2010 Jun; 42(5):1667-70. PubMed ID: 20620496 [TBL] [Abstract][Full Text] [Related]
52. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment. Yoshimura N; Ushigome H; Matsuyama M; Nobori S; Suzuki T; Sakai K; Okajima H; Okamoto M Transplant Proc; 2012 Jan; 44(1):140-3. PubMed ID: 22310599 [TBL] [Abstract][Full Text] [Related]
53. Obesity in renal transplantation: the role of induction therapy on long-term outcomes. Patel S; Pankewycz O; Kohli R; Said M; Alnimri M; Feng L; Laftavi MR Transplant Proc; 2011 Mar; 43(2):469-71. PubMed ID: 21440736 [TBL] [Abstract][Full Text] [Related]
54. Selection of induction therapy in kidney transplantation. Hardinger KL; Brennan DC; Klein CL Transpl Int; 2013 Jul; 26(7):662-72. PubMed ID: 23279211 [TBL] [Abstract][Full Text] [Related]
55. [Monoclonal antibodies in renal transplantation]. Bonvoisin C; Weekers L; Grosch S; Krzesinski JM Rev Med Liege; 2009; 64(5-6):287-92. PubMed ID: 19642461 [TBL] [Abstract][Full Text] [Related]
56. Use of antibody induction in pediatric renal transplantation. Pescovitz MD Curr Opin Organ Transplant; 2008 Oct; 13(5):495-9. PubMed ID: 19060532 [TBL] [Abstract][Full Text] [Related]
57. The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts. Goh BK; Chedid MF; Gloor JM; Raghavaiah S; Stegall MD Transpl Immunol; 2012 Oct; 27(2-3):95-100. PubMed ID: 22813834 [TBL] [Abstract][Full Text] [Related]
58. Anti-IL-2 receptor antibodies versus anti-thymocyte globulin for induction therapy in kidney transplantation. Mandelbrot D J Am Soc Nephrol; 2009 Jun; 20(6):1170-1. PubMed ID: 19470672 [No Abstract] [Full Text] [Related]
59. Induction therapies in kidney transplantation: the experience of Hospital Pablo Tobon Uribe, Medellín, Colombia 2005-2010. Ocampo C; Aristizabal A; Nieto J; Abadia H; Angel W; Guzman C; Mena A; Vanegas J; Velez C; Aguirre C; Yepes C; Zuluaga G Transplant Proc; 2011 Nov; 43(9):3359-63. PubMed ID: 22099796 [TBL] [Abstract][Full Text] [Related]
60. Ten-year follow-up of basiliximab induction therapy for live-donor kidney transplant: a prospective randomized controlled study. Sheashaa HA; Bakr MA; Rashad RH; Ismail AM; Sobh MA; Ghoneim MA Exp Clin Transplant; 2011 Aug; 9(4):247-51. PubMed ID: 21819369 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]